Scott Laboratories is thrilled to announce the U.S. approval of the first and only non-Oenococcus strain for malolactic fermentation. The approved strain, Lactiplantibacillus plantarum DSM 34613, is available exclusively from Scott Laboratories as ML PRIME™ and is now officially listed under 27 CFR 24.250.

Originally isolated by the Università Cattolica del Sacro Cuore in Italy, the strain underwent extensive research and development by Lallemand Oenology to evaluate its suitability for winemaking. While recently approved in the U.S., ML PRIME has been used globally for over 10 years.

Ideal for co-inoculation, ML PRIME™ rapidly completes malolactic fermentation. Unlike O. oeni strains, ML PRIME™ does not produce volatile acidity from glucose, fructose, or citric acid, a common risk associated with uncontrolled co-inoculation with O. oeni.

“We are excited to bring ML PRIME™ to the US market,” said Dr. Nichola Hall of Scott Laboratories. “As a microbiologist, this organism is fascinating and unique in the world of wine microorganisms. As a winemaker, it is exciting as it offers a safe and efficient route to complete malolactic fermentation, allowing quick tank turnover and minimizing post-fermentation monitoring while still enhancing wine quality.”

The approval of ML PRIME™ reflects Scott Laboratories’ ongoing commitment to offering diverse, research-driven solutions that meet the evolving needs of winemakers. It joins Scott Labs’ comprehensive portfolio of malolactic bacteria, which includes a broad range of O. oeni strains known for their proven performance and sensory impact across a wide variety of wine styles and conditions.

For technical resources, application guidelines, or ordering information, visit scottlab.com or call (707) 765-6666.